keyword
MENU ▼
Read by QxMD icon Read
search

mCRPC

keyword
https://www.readbyqxmd.com/read/28729067/real-world-characteristics-and-outcomes-of-patients-with-metastatic-castration-resistant-prostate-cancer-receiving-chemotherapy-versus-androgen-receptor-targeted-therapy-after-failure-of-first-line-androgen-receptor-targeted-therapy-in-the-community-setting
#1
William K Oh, Raymond Miao, Francis Vekeman, Jennifer Sung, Wendy Y Cheng, Marjolaine Gauthier-Loiselle, Ravinder Dhawan, Mei Sheng Duh
BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), optimal treatment sequences are unknown. We assessed second-line taxane (TT) versus androgen receptor-targeted therapy (ART), after initial ART failure, in United States oncology community practices. PATIENTS AND METHODS: Using electronic medical records, patients with mCRPC receiving first-line ART and second-line therapy (TT, ART) were identified. Response and overall survival (OS) were evaluated from second-line therapy initiation...
June 19, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28725594/weekly-ascorbic-acid-infusion-in-castration-resistant-prostate-cancer-patients-a-single-arm-phase-ii-trial
#2
Torben K Nielsen, Martin Højgaard, Jon T Andersen, Niklas Rye Jørgensen, Bo Zerahn, Bent Kristensen, Trine Henriksen, Jens Lykkesfeldt, Kári J Mikines, Henrik E Poulsen
BACKGROUND: Ascorbic acid (AA) has in vivo cytotoxic properties at concentrations that can only be achieved through intravenous (IV) administration in humans. Treatment with intravenous AA is widely and increasingly used in complementary medicine despite a lack of clinical evidence for the efficacy of this treatment. METHODS: This non-comparative, single-center, phase II trial included patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) from an outpatient clinic to evaluate the efficacy and safety of IV AA therapy...
June 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28723521/bone-scan-index-and-progression-free-survival-data-for-progressive-metastatic-castration-resistant-prostate-cancer-patients-who-received-odm-201-in-the-arades-multicentre-study
#3
Mariana Reza, Robert Jones, John Aspegren, Christophe Massard, Leena Mattila, Mika Mustonen, Per Wollmer, Elin Trägårdh, Eva Bondesson, Lars Edenbrandt, Karim Fizazi, Anders Bjartell
BACKGROUND: ODM-201, a new-generation androgen receptor inhibitor, has shown clinical efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess changes in bone as a measurement of treatment response. The Bone Scan Index (BSI) reflects the percentage of skeletal mass a given tumour affects. OBJECTIVE: To evaluate the predictive value of the BSI in metastatic castration-resistant PCa (mCRPC) patients undergoing treatment with ODM-201...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723520/bone-scan-index-as-an-imaging-biomarker-in-metastatic-castration-resistant-prostate-cancer-a-multicentre-study-based-on-patients-treated-with-abiraterone-acetate-zytiga-in-clinical-practice
#4
Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck-Lissbrant, Jan-Erik Damber, Anders Widmark, Camilla Thellenberg-Karlsson, Lars Budäus, Thomas Steuber, Till Eichenauer, Per Wollmer, Lars Edenbrandt, Elin Trägårdh, Anders Bjartell
BACKGROUND: Abiraterone acetate (AA) prolongs survival in metastatic castration-resistant prostate cancer (mCRPC) patients. To measure treatment response accurately in bone, quantitative methods are needed. The Bone Scan Index (BSI), a prognostic imaging biomarker, reflects the tumour burden in bone as a percentage of the total skeletal mass calculated from bone scintigraphy. OBJECTIVE: To evaluate the value of BSI as a biomarker for outcome evaluation in mCRPC patients on treatment with AA according to clinical routine...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723519/individual-patient-data-analysis-of-randomized-clinical-trials-impact-of-black-race-on-castration-resistant-prostate-cancer-outcomes
#5
Daniel E Spratt, Yu-Wei Chen, Brandon A Mahal, Joseph R Osborne, Shuang G Zhao, Todd M Morgan, Ganesh Palapattu, Felix Y Feng, Paul L Nguyen
BACKGROUND: Population data suggest that black men have a higher risk of dying from prostate cancer (PCa) than other racial ethnicities. OBJECTIVE: To examine the impact of black race on progression-free survival (PFS) and overall survival (OS) among men with metastatic castration-resistant PCa (mCRPC) enrolled in randomized controlled trials (RCTs). DESIGN, SETTING, AND PARTICIPANTS: A pooled analysis was performed on individual patient data from five modern PCa RCTs available from Project Data Sphere...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723515/understanding-mechanisms-of-resistance-in-metastatic-castration-resistant-prostate-cancer-the-role-of-the-androgen-receptor
#6
REVIEW
Derya Tilki, Edward M Schaeffer, Christopher P Evans
CONTEXT: After initiation of androgen deprivation therapy (ADT), most patients progress to castration-resistant prostate cancer (CRPC) within 2 or 3 yr. In the USA, approximately 67000 men are estimated to have metastatic CRPC. OBJECTIVE: To provide an overview of different mechanisms driving resistance to therapy in metastatic CRPC, with a focus on androgen receptor (AR)-dependent pathways. EVIDENCE ACQUISITION: A Medline search via PubMed was performed using the keywords metastatic castration resistant prostate cancer (mCRPC), castration-resistant, CRPC, prostate cancer, androgen resistance, hormone-refractory, hormone-independent, androgen receptor, and androgen receptor axis...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723514/optimal-treatment-sequence-for-metastatic-castration-resistant-prostate-cancer
#7
REVIEW
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S de Bono
CONTEXT: Unprecedented development of therapeutics for prostate cancer in recent years has left clinicians with the challenge of adequately sequencing therapeutic agents to optimise patient benefit. No clear guidelines exist on optimal treatment sequences. OBJECTIVE: To summarise the evidence on first-line activity, cross-resistance, and potential combinations of agents approved for metastatic castration-resistant prostate cancer (mCRPC). EVIDENCE ACQUISITION: A nonsystematic literature search of articles on agent sequencing in mCRPC in PubMed and relevant cancer conferences up to June 2016 was performed...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723513/the-natural-history-and-outcome-predictors-of-metastatic-castration-resistant-prostate-cancer
#8
REVIEW
Robert J van Soest, Jason A Efstathiou, Cora N Sternberg, Bertand Tombal
CONTEXT: Biomarkers for the treatment of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed by clinicians to facilitate treatment decisions. OBJECTIVE: To review current prognostic and predictive biomarkers in mCRPC. EVIDENCE ACQUISITION: We performed a nonsystematic review of the literature from 2004 to August 2016 by searching in Medline. Cross-matching references were used to search for additional articles. We reviewed clinical research and review articles written in the English language...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723508/targeting-adaptive-pathways-in-metastatic-treatment-resistant-prostate-cancer-update-on-the-stand-up-2-cancer-prostate-cancer-foundation-supported-west-coast-prostate-cancer-dream-team
#9
Rahul Aggarwal, Tomasz M Beer, Martin Gleave, Joshua M Stuart, Matthew Rettig, Christopher P Evans, Jack Youngren, Joshi J Alumkal, Jiaoti Huang, George Thomas, Owen Witte, Eric J Small
The Stand Up 2 Cancer/Prostate Cancer Foundation-funded West Coast Dream Team project is a prospective multi-institutional study focused on acquiring metastatic castration-resistant prostate cancer (mCRPC) biopsy tissue at the time of resistance to abiraterone or enzalutamide. It is the first large-scale study designed to analyze mCRPC tissue specifically in this patient population. Study accrual is on target, with 261 out of a planned 300 metastatic tumor biopsies performed by August 2016. Paired biopsies have been completed in 42 patients, with paired genomic data before and after therapy obtained in 26 cases...
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723506/biomarkers-for-metastatic-castration-resistant-prostate-cancer-mcrpc-yes-or-no-predictive-and-response-biomarkers-towards-precision-medicine-in-mcrpc
#10
Joaquin Mateo
Advances in drug development and molecular studies for castration-resistant prostate cancer (CRPC) render the possibility of more efficient and precise patient care through the use of predictive, response, and resistance biomarkers. Thorough scrutiny of assay validation and clinical qualification processes for biomarkers in development, ideally in parallel with clinical trials, is critical for the success of personalised medicine in CRPC management.
December 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723476/charting-recent-progress-and-challenges-in-metastatic-castration-resistant-prostate-cancer-is-there-an-optimal-treatment-sequence
#11
REVIEW
Stéphane Oudard, Pablo Maroto, Gaston Demonty, Winald R Gerritsen
CONTEXT: Recent developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have led to uncertainty about the optimal sequence of agents. OBJECTIVE: To review and assess treatment options and sequence in patients with mCRPC. EVIDENCE ACQUISITION: To identify data on the optimal use of approved treatments, we searched PubMed for studies on the use of recently approved agents for men with mCRPC published before March 2015...
October 2016: European Urology Focus
https://www.readbyqxmd.com/read/28718092/no-significant-impact-of-prior-treatment-profile-with-docetaxel-on-the-efficacy-of-cabazitaxel-in-japanese-patients-with-metastatic-castration-resistant-prostate-cancer
#12
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
The objective of this study was to retrospectively analyze the oncological outcomes of Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel. This study included a total of 63 consecutive Japanese mCRPC patients treated with cabazitaxel following the failure of docetaxel, and assessed the prognostic significance of cabazitaxel therapy in these patients focusing on the association of efficacies between two taxane agents. After treatment with cabazitaxel (median 5 cycles), prostate-specific antigen (PSA) decline was observed in 39 patients (61...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28718070/platelet-lymphocyte-and-neutrophil-lymphocyte-ratios-are-prognostic-but-not-predictive-of-response-to-abiraterone-acetate-in-metastatic-castration-resistant-prostate-cancer
#13
A J Lozano Martínez, R Moreno Cano, S Escobar Páramo, R Salguero Aguilar, E Gonzalez Billalabeitia, R García Fernández, I De La Fuente Muñoz, A Romero Borque, M Porras Martínez, F Lopez Soler, E Cardenas Cánovas, I Ortega Martín
PURPOSE: Recently neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been reported to be inflammatory parameters that confer poorer outcome in metastatic castration-resistant prostate cancer (mCPRPC). However, these ratios have not been analyzed in patients treated with abiraterone acetate. We explored the relationship between different values of PLR and NLR and survival in mCPRCP treated with abiraterone and their possible relation with a prostate specific antigen (PSA) response...
July 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28716060/nonlinear-joint-models-for-individual-dynamic-prediction-of-risk-of-death-using-hamiltonian-monte-carlo-application-to-metastatic-prostate-cancer
#14
Solène Desmée, France Mentré, Christine Veyrat-Follet, Bernard Sébastien, Jérémie Guedj
BACKGROUND: Joint models of longitudinal and time-to-event data are increasingly used to perform individual dynamic prediction of a risk of event. However the difficulty to perform inference in nonlinear models and to calculate the distribution of individual parameters has long limited this approach to linear mixed-effect models for the longitudinal part. Here we use a Bayesian algorithm and a nonlinear joint model to calculate individual dynamic predictions. We apply this approach to predict the risk of death in metastatic castration-resistant prostate cancer (mCRPC) patients with frequent Prostate-Specific Antigen (PSA) measurements...
July 17, 2017: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/28711312/radium-223-in-the-therapeutic-sequence-of-metastatic-castration-resistant-prostate-cancer
#15
M Unda-Urzaiz, R Sousa-Campo, A Rodríguez-Antolín, C Silva-Marins, A Juárez-Soto, B Miñana-López, A Figueiredo-de Castro, J M Cozar-Olmos
CONTEXT: Radium-223 is an □ -particle transmitter with specific action on bone metastases. The Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study showed that radium-223 extended overall survival and delayed the onset of bone events in patients with symptomatic castration-resistant prostate cancer with bone metastases (mCRPC) and without visceral metastases, with a good safety profile. OBJECTIVE: To review the new scientific evidence on radium-223 based on prespecified and post-hoc analyses of the ALSYMPCA study and on early-access programs after the publication of the ALSYMPCA study, thereby providing new data on the management of patients with mCRPC...
July 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28707844/castration-resistance-prostate-cancer-what-is-in-the-pipeline
#16
Cosimo DE Nunzio, Fabrizio Presicce, Silvana Giacinti, Maria Bassanelli, Andrea Tubaro
INTRODUCTION: To evaluate the available evidence on the standard diagnosis and management of men with metastatic castration resistant prostate cancer (mCRPC), and providing the timely update on new pharmacological treatments. EVIDENCE ACQUISITION: A systematic literature search from from January 2000 until March 2017 was performed by combining the following MESH terms: castrate resistant prostate cancer, abiraterone, enzalutamide, 223radium, sipuleucel-T, docetaxel, cabazitaxel, resistance mechanisms, resistance to androgen deprivation, Androgen Receptor (AR) mutations, amplifications, splice variants, and AR alterations...
July 12, 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/28700990/oncologic-response-and-hospitalization-rate-of-patients-receiving-cabazitaxel-in-the-fourth-line-and-beyond-in-castration-resistant-prostate-cancer-analysis-of-a-retrospective-cohort-and-a-structured-literature-review
#17
Jost von Hardenberg, Maike Schwartz, Thorsten Werner, Stefan Fuxius, Arne Strauss, Thomas Stefan Worst, Philipp Nuhn, Christian Bolenz, Elmar Heinrich
BACKGROUND: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. PATIENTS AND METHODS: We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review...
July 13, 2017: Urologia Internationalis
https://www.readbyqxmd.com/read/28695267/impact-of-an-alternative-steroid-on-the-relative-bioavailability-and-bioequivalence-of-a-novel-versus-the-originator-formulation-of-abiraterone-acetate
#18
Azra Hussaini, Anthony J Olszanski, Cy A Stein, Bill Bosch, Paul Nemeth
PURPOSE: The originator abiraterone acetate (OAA) formulation is used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the bioavailability and bioequivalence of a novel formulation, abiraterone acetate fine particle (AAFP), versus OAA on a steady-state background of steroids. METHODS: Thirty-seven healthy male subjects were randomized in a crossover design to receive methylprednisolone (4 mg twice daily) or prednisone (5 mg twice daily) for 12 days in Period 1...
July 10, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28695241/-metastatic-prostate-cancer-update-position-paper-for-the-use-of-chemotherapy
#19
REVIEW
C-H Ohlmann, P J Goebell, M-O Grimm, J Klier, F König, S Machtens, M Schostak, A-J Schrader, P Albers
BACKGROUND: Taxen-based chemotherapy has been established as an effective treatment option in castration-resistant metastatic prostate cancer (mCRPC). Randomized phase III studies, however, have shown that even in the hormone-naïve metastatic state, the early use of chemotherapy in addition to the classical androgen deprivation therapy (ADT) approach leads to a significant increase in median overall survival. OBJECTIVE: This position paper aims to provide current data and orientation in the evidence-based treatment of mPC patients in daily clinical practice...
July 10, 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/28676659/mutations-in-brca2-and-taxane-resistance-in-prostate-cancer
#20
Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich, Stefan Duensing
Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation...
July 4, 2017: Scientific Reports
keyword
keyword
85742
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"